Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT
Latest Information Update: 11 Oct 2024
Price :
$35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Acronyms ENLIGHT
- Sponsors Novartis Pharmaceuticals
- 08 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2023 Status changed from not yet recruiting to recruiting.
- 17 Aug 2023 New trial record